ICON and Tigermed Sign Alliance Agreement in China
ICON and Tigermed Consulting announced that they have signed an alliance agreement. Through this agreement, ICON and Tigermed will collaborate to offer pharmaceutical and biotechnology clients better access to Chinese patients, utilizing the global reach and experience of the ICON organization, complemented by Tigermed’s in depth knowledge of the Chinese drug development landscape and geographic coverage in China. With headquarters in Shanghai, Tigermed currently operates from 21 offices in China and has over 300 clinical development staff located there.
“Tigermed has a substantial clinical operations presence on the Chinese mainland and this experience, gives them the ability to provide wide-ranging support for clinical drug development in China.” commented Dr. John Hubbard, Group President, Global Clinical Research Services at ICON.
“We are extremely pleased to have signed this agreement with ICON” commented Xiaoping Ye, Chairman and CEO of Tigermed. “This alliance enhances our regional and global capabilities and will enable both ICON and Tigermed to expand the range of clinical research services we can offer to clients in China and around the globe.”
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Ifinatamab Deruxtecan Shows High Response Rates for Heavily Pretreated Small Cell Lung Cancer
September 9th 2024Potential first-in-class B7-H3 directed antibody drug conjugate ifinatamab deruxtecan shows potential to improve outcomes for patients living with difficult-to-treat form of lung cancer.
